Pancreatic cancer stage four used to mean a grim prognosis—chemo offered only months of survival. But now, a new experimental drug called daraxonrasib is changing the game. Former Senator Ben Sasse, who’s living with stage four pancreatic cancer, reports dramatic improvement. Targeting the genetic roots of the disease, daraxonrasib doubled survival rates in early trials—pushing median survival from 6.5 months to 13 months. Though not yet FDA-approved, patients in good health can access it through an expanded access program. Call 844-CURPANC for details.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
